Scopus BioPharma (SCPS) Stock Price, News & Analysis

Company Overview

Scopus BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for central nervous system disorders. The company’s research efforts are aimed at addressing unmet medical needs in neuropathic pain, migraine and mood disorders by leveraging proprietary small-molecule platforms designed to modulate key neural pathways.

The company’s product pipeline comprises both clinical- and preclinical-stage candidates. Its lead programs include small-molecule compounds intended to provide relief in patients suffering from chronic neuropathic pain and episodic migraine. Scopus BioPharma applies a translational research approach, integrating biomarkers and patient-stratification strategies to enhance the probability of clinical success.

Headquartered in Newtown, Pennsylvania, Scopus BioPharma conducts its research and early development activities in the United States, with collaborations across academic and clinical research centers. By forging strategic partnerships, the company seeks to accelerate development timelines and broaden access to its investigational therapies.

Scopus BioPharma is led by a management team with extensive experience in pharmaceutical development and regulatory affairs. The company’s governance and operational infrastructure are structured to support efficient clinical trial execution and to advance its portfolio toward potential regulatory approval and commercialization.

Key Stats

• Today's Range: $0.0004 to $0.0004
• 50-Day Range: N/A
• 52-Week Range: $0.0003 to $0.01
• Volume: 3,042 shs
• Average Volume: 3,462 shs
• Market Capitalization: $16.83 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SCPS Stock Analysis - Frequently Asked Questions

How have SCPS shares performed this year?

Scopus BioPharma's stock was trading at $0.0004 at the beginning of the year. Since then, SCPS shares have increased by 0.0% and is now trading at $0.0004.

How do I buy shares of Scopus BioPharma?

Shares of SCPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scopus BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scopus BioPharma investors own include Plug Power (PLUG), Canoo (GOEV), NIO (NIO), SNDL (SNDL), Tesla (TSLA), Moderna (MRNA) and VYNE Therapeutics (VYNE).

Company Calendar

• Today: 5/05/2026
• Next Earnings (Estimated): 6/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCPS
• CIK: 1772028
• Web: scopusbiopharma.com
• Phone: 212-479-2513
• Fax: N/A
• Employees: 9
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 42,080,000
• Free Float: 39,938,000
• Market Cap: $16.83 thousand
• Optionable: Not Optionable
• Beta: -0.26